Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences
August 31 2021 - 8:30AM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that Kevin R. Lind, Longboard’s President & Chief Executive
Officer, will present virtually in a fireside chat format at two
upcoming investor conferences: Citi’s 16th Annual BioPharma Virtual
Conference and H.C. Wainwright’s 23rd Annual Global Investment
Conference.
- Citi’s BioPharma
Conference: Wednesday, September 8, 2021, at 3:15 PM
ET
- H.C. Wainwright’s Global
Investment Conference: Webcast available beginning Monday,
September 13, 2021, at 7:00 AM ET
To access live webcasts of Longboard’s
presentations, please visit the “Events & Presentations” page
within the Investors Relations section of Longboard’s website at
https://ir.longboardpharma.com/. Replays of the webcasts will be
available shortly after the completion of the events and archived
on the website for at least 30 days.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard was
formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to
advance a portfolio of centrally acting product candidates designed
to be highly selective for specific G protein-coupled receptors
(GPCRs). Longboard’s small molecule product candidates were
discovered out of the same platform at Arena that represents a
culmination of more than 20 years of GPCR research. Longboard is
evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c
receptor subtype superagonist, with negligible observed impact on
5-HT2b and 5-HT2a receptor subtypes, in development for the
potential treatment of developmental and epileptic
encephalopathies. Longboard is also evaluating LP143, a centrally
acting, full cannabinoid type 2 receptor agonist, in development
for the potential treatment of neurodegenerative diseases
associated with neuroinflammation caused by microglial activation,
and LP659, a centrally acting, sphingosine-1-phosphate receptor
subtypes 1 and 5 modulator, in development for the potential
treatment of central nervous system neuroinflammatory diseases.
Forward-Looking
StatementsCertain statements in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Such forward-looking statements include statements
about Longboard’s participation in the upcoming conferences,
clinical and preclinical programs, ability to develop medicines,
and focus. For such statements, Longboard claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events
or results may differ materially from Longboard’s expectations.
Factors that could cause actual results to differ materially from
those stated or implied by Longboard’s forward-looking statements
are disclosed in Longboard’s filings with the Securities and
Exchange Commission (SEC). These forward-looking statements
represent Longboard’s judgment as of the time of this release.
Longboard disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024